Table of Contents:


1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Scope of Study
3.2 Research Objective
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Primary Research
4.2 Secondary Research
4.3 Market Size Estimation
4.4 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 All-rounder (Both diagnostic & treatment), characteristics of radiopharmaceutical driving
the market growth (35%) 34
5.2.2 Increasing Prevalence of Chronic Diseases (20%)
5.2.3 Increasing Expenditure on Oncology Medicine (25%)
5.2.4 Increasing use of radiopharmaceuticals for the diagnosis & treatment of chronic diseases in
the elderly population (20%) 37
5.3 Restraints
5.3.1 The high cost of radiopharmaceuticals (55%)
5.3.2 Side Effects of Radiation Exposure (45%)
5.4 Opportunity
5.4.1 Potential radioisotopes in the pipeline
6 Market Factor Analysis
6.1 Porter's Five Forces Model
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Intensity of Rivalry
6.2 Value Chain Analysis
6.2.1 Research & Product Development
6.2.2 Manufacturing
6.2.3 Distribution & Sales
6.2.4 Post-Sales Monitoring
6.3 Procedure Numbers
7 Global Radiopharmaceutical Market, by Type
7.1 Introduction
7.1.1 Diagnostic Type
7.1.2 Therapeutic Type
8 Global Radiopharmaceuticals Market, by Type of Test
8.1 Introduction
8.1.1 Bone Scan
8.1.2 Myocardial Perfusion Scan
8.1.3 Parathyroid Scan
8.1.4 Renal Nuclear Medicine Scan
8.1.5 Lung Scan
8.1.6 Gallium Scan
8.1.7 White Blood Cell Scan
8.1.8 Hepatobiliary Scan
8.1.9 Cerebral Perfusion Scan
9 Global Radiopharmaceutical Market, by Application
9.1 Introduction
9.1.1 Oncology
9.1.2 Cardiology
9.1.3 Neurology
9.1.4 Urology
10 Global Radiopharmaceutical Market, by Route of Administration
10.1 Introduction
10.1.1 Oral
10.1.2 Intravenous
?
11 Global Radiopharmaceutical Market, by End-User
11.1 Introduction
11.1.1 Hospitals
11.1.2 Diagnostic Centers
11.1.3 Research Institutes
12 Global Radiopharmaceutical Market, by Region
12.1 Introduction
12.2 Americas
12.2.1 North America
12.2.1.1 U.S.
12.2.1.2 Canada
12.2.2 South America
12.3 Europe
12.3.1 Western Europe
12.3.1.1 Germany
12.3.1.2 France
12.3.1.3 UK
12.3.1.4 Italy
12.3.1.5 Spain
12.3.1.6 Rest of Western Europe
12.3.2 Eastern Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 Republic of Korea
12.4.6 Rest of Asia Pacific
12.5 The Middle East & Africa
12.5.1.1 Middle East
12.5.1.2 Africa
13 Competitive Landscape
13.1 Company Market Share Analysis
13.1.1 Introduction
13.1.2 Company Share Analysis
13.2 Recent Developments, 2013-2018
14 Company Profile
14.1 Jubilant Life Sciences Ltd.
14.1.1 Company Overview
14.1.2 Financial Overview
14.1.3 Products Offerings
14.1.4 Key Developments
14.1.5 SWOT Analysis
14.1.6 Key Strategy
14.2 Siemens AG
14.2.1 Company Overview
14.2.2 Financial Overview
14.2.3 Products Offerings
14.2.4 Key Developments
14.2.5 SWOT Analysis
14.2.6 Key Strategy
14.3 Sun Pharmaceutical Industries Ltd.
14.3.1 Company Overview
14.3.2 Financial Overview
14.3.3 Products Offerings
14.3.4 Key Developments
14.3.5 SWOT Analysis
14.3.6 Key Strategy
14.4 Bayer AG
14.4.1 Company Overview
14.4.2 Financial Overview
14.4.3 Products Offerings
14.4.4 Key Developments
14.4.5 SWOT Analysis
14.4.6 Key Strategy
14.5 Cardinal Health Inc.
14.5.1 Company Overview
14.5.2 Financial Overview
14.5.3 Products Offerings
14.5.4 Key Developments
14.5.5 SWOT Analysis
14.5.6 Key Strategy
14.6 Medtronic
14.6.1 Company Overview
14.6.2 Financial Overview
14.6.3 Products Offerings
14.6.4 Key Developments
14.6.5 SWOT Analysis
14.6.6 Key Strategy
14.7 General Electric Company (GE Healthcare)
14.7.1 Company Overview
14.7.2 Financial Overview
14.7.3 Products Offerings
14.7.4 Key Developments
14.7.5 SWOT Analysis
14.7.6 Key Strategy
14.8 Lantheus Medical Imaging, Inc.
14.8.1 Company Overview
14.8.2 Financial Overview
14.8.3 Products Offerings
14.8.4 Key Developments
14.8.5 SWOT Analysis
14.8.6 Key Strategy
14.9 Advanced Accelerator Applications S.A.
14.9.1 Company Overview
14.9.2 Financial Overview
14.9.3 Products Offerings
14.9.4 Key Developments
14.9.5 SWOT Analysis
14.9.6 Key Strategy
14.1 Mallinckrodt Pharmaceuticals
14.10.1 Company Overview
14.10.2 Financial Overview
14.10.3 Products Offerings
14.10.4 Key Developments
14.10.5 SWOT Analysis
14.10.6 Key Strategy
14.11 Nordion, Inc.
14.11.1 Company Overview
14.11.2 Financial Overview
14.11.3 Products Offerings
14.11.4 Key Developments
14.11.5 SWOT Analysis
14.11.6 Key Strategy
14.12 Canadian Nuclear Laboratories (CNL)
14.12.1 Company Overview
14.12.2 Financial Overview
14.12.3 Products Offerings
14.12.4 Key Developments
14.12.5 SWOT Analysis
14.12.6 Key Strategy
14.13 Bracco Diagnostic Inc.
14.13.1 Company Overview
14.13.2 Financial Overview
14.13.3 Products Offerings
14.13.4 Key Developments
14.13.5 SWOT Analysis
14.13.6 Key Strategy
14.14 IBA Dosimetry GmbH
14.14.1 Company Overview
14.14.2 Financial Overview
14.14.3 Products Offerings
14.14.4 Key Developments
14.14.5 SWOT Analysis
14.14.6 Key Strategy
14.15 Avid Radiopharmaceuticals
14.15.1 Company Overview
14.15.2 Financial Overview
14.15.3 Products Offerings
14.15.4 Key Developments
14.15.5 SWOT Analysis
14.15.6 Key Strategy
15 Appendix
15.1 Discussion Blue Print